MWX205
/ Minwei Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 09, 2026
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205
(clinicaltrials.gov)
- P1 | N=37 | Not yet recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd
New P1 trial • Dyslipidemia • Metabolic Disorders
1 to 1
Of
1
Go to page
1